Astellas and Evopoint sign ADC licensing deal
Astellas will develop and commercialise the ADC, excluding mainland China, Macao, Hong Kong and the Taiwan region.
Drug Development
CHMP recommends GSK’s Blenrep approval for multiple myeloma treatment
Viralgen and Trogenix to progress gene therapy for glioblastoma
Construction begins on MSD’s $1bn biologics centre in Delaware, US
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
DAAN Biotherapeutics and GC Cell partner for CAR-T, CAR-NK therapies
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Boehringer and Cue Biopharma to develop autoimmune therapies
